Adaptive Biotechnologies ( (ADPT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptive Biotechnologies’ stock is on the rise after Guggenheim initiated coverage with a Buy rating. The firm highlighted the company’s strong position in minimal residual disease blood cancer tests and its potential for sustained revenue growth. Guggenheim believes that market conversion, penetration into new indications, and price increases will fuel future growth. Additionally, the shares are trading at a significant discount compared to other leading cancer specialty lab companies.
More about Adaptive Biotechnologies
YTD Price Performance: 117.45%
Average Trading Volume: 1,911,640
Technical Sentiment Signal: Buy
Current Market Cap: $2.05B
For further insights into ADPT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.